FDA Requires New Eye-Risk Warning for All GLP-1 Drugs

On November 9, 2026, FDA announced that it is requiring application holders for all GLP-1 receptor agonists to add a warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). The new language goes in the Warnings and Precautions section of labeling. FDA's list of covered products includes semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo), along with liraglutide, dulaglutide, exenatide and lixisenatide products. [1]

What FDA found, and what it did not

NAION is a rare condition that can cause sudden, painless vision loss, typically in one eye, and the loss can be permanent. FDA says NAION cases have been reported for every currently marketed GLP-1 product. [1]

FDA's review drew on a meta-analysis of 126 randomized trials, a Sentinel cohort study and published observational research. In the trial data, probable NAION occurred at 6.4 per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo. FDA also noted that its animal data did not identify a mechanism. [1]

The communication describes a potential increased risk. It does not establish that a GLP-1 drug caused any individual patient's condition. It also sets no universal implementation deadline for clinics.

What telehealth weight-management programs should do now

FDA hasn't set a deadline for clinics, but the new warning raises the standard for informed consent and follow-up care. Telehealth practices, prescribers, pharmacy partners and supporting MSOs should have clinical leadership review the following now:

1. Patient counseling. Tell patients to report right away any sudden, painless vision loss, blurred or missing areas of vision, or color distortion in one eye.
2. Consent materials. Update intake and informed-consent forms to describe the NAION risk the way FDA describes it, as a potential increased risk.
3. Symptom triage. Make sure asynchronous and messaging workflows flag visual complaints for prompt clinician review rather than routine queues.
4. Referral pathway. FDA advises prompt ophthalmology referral when NAION is suspected. Remote programs should know how they will get patients to an in-person eye exam quickly.
5. Ongoing therapy. FDA says prescribers should consider discontinuing the GLP-1 in patients who develop NAION unless benefits clearly outweigh the risk. Patients with a prior NAION history face a higher risk of recurrence, which belongs in screening.
6. Adverse-event procedures. Confirm who documents and reports suspected cases, including through FDA's MedWatch program.

Pharmacy partners and MSOs should confirm that patient-facing materials, scripts and platform content are updated consistently across the network. MSOs should avoid directing clinical decisions; the clinical protocol changes belong to the professional entity's medical leadership.

Primary sources

1. FDA Drug Safety Communication: FDA requires safety labeling changes for GLP-1 receptor agonists due to potential risk of NAION (Nov. 9, 2026).

This article provides general legal and regulatory information as of November 10, 2026 and is not legal or medical advice. Clinical decisions belong to licensed prescribers.